Compare HBAN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBAN | UTHR |
|---|---|---|
| Founded | 1866 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 23.9B |
| IPO Year | N/A | 1999 |
| Metric | HBAN | UTHR |
|---|---|---|
| Price | $15.00 | $523.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 14 |
| Target Price | $19.38 | ★ $531.79 |
| AVG Volume (30 Days) | ★ 25.2M | 497.9K |
| Earning Date | 04-16-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $50.66 | $7.05 |
| Revenue Next Year | $9.04 | $13.30 |
| P/E Ratio | ★ $12.87 | $18.93 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $11.92 | $266.98 |
| 52 Week High | $19.44 | $548.12 |
| Indicator | HBAN | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 56.10 |
| Support Level | N/A | $464.92 |
| Resistance Level | $16.28 | $542.66 |
| Average True Range (ATR) | 0.39 | 13.44 |
| MACD | -0.09 | 0.51 |
| Stochastic Oscillator | 9.81 | 70.23 |
Huntington is a regional US bank with over $200 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.